



(12) UK Patent (19) GB (11) 2 202 145 (13) B

(54) Title of Invention

Compositions of Nedocromil for  
Dermatological use.

(51) INT CL<sup>5</sup>; A61K 31/395

(21) Application No  
8804697.4

(22) Date of filing  
29 Feb 1988

(30) Priority Data

(31) 8706242  
8800833

(32) 17 Mar 1987  
14 Jan 1988

(33) GB

(43) Application published  
21 Sep 1988

(45) Patent published  
02 Jan 1991

(52) Domestic classification  
(Edition K)  
A5B BHA B170 B50Y B501  
B503 B55Y B550 B551 B57Y  
B576 B61Y B616  
U1S S2416

(56) Documents cited  
GB2157291 A  
EP0279121 A2  
J. Med. Chem. 28(12)  
1832-42 (1985) Cairns et al.

(58) Field of search

As for published application  
2202145 A viz:  
UK CL A5B  
INT CL A61K  
updated as appropriate

Additional Fields  
ONLINE DATABASE:  
CAS-ONLINE

(73) Proprietor(s)  
Fisons Plc

(Incorporated in the United  
Kingdom)

Fison House  
Princes Street  
Ipswich  
Suffolk  
IP1 1QH  
United Kingdom

(72) Inventor(s)  
Dr Joseph Wilson Totten  
Dr Kenneth Andrew Walters

(74) Agent and/or  
Address for Service  
Stephen Anthony JONES  
Fisons plc  
12 Derby Road  
Loughborough  
Leicestershire  
LE11 0BB  
United Kingdom



COMPOSITIONS OF NEDOCROMIL FOR DERMATOLOGICAL USE

This invention relates to pharmaceutical compositions, methods for their preparation and methods of treatment using them.

5 UK Patent 2022078 discloses a number of pyranoquinolines which are indicated for use in the treatment of, inter alia, reversible airways obstruction. These compounds are described as being administered oesophageally or by inhalation. UK Patent application  
10 2157291 discloses a pressurised aerosol formulation of one of these pyranoquinolines, known as nedocromil sodium, which is the disodium salt of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid, also for the treatment of reversible airways  
15 obstruction.

In general, the pyranoquinoline compounds disclosed in the above references are highly polar, hydrophilic molecules. As such they would not be expected to be absorbed through the skin to a sufficient extent to provide  
20 therapeutic levels of the compounds in the sub-epithelial tissues.

Surprisingly, however, we have now found that compositions containing as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-  
25 pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a

pharmaceutically acceptable derivative thereof are effective in the treatment of certain dermatological disorders when applied topically to the skin.

According to the invention there is provided a  
5 pharmaceutical composition in the form of a cream, ointment or dusting powder, comprising, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable derivative thereof in admixture  
10 with a pharmaceutically acceptable adjuvant or excipient.

Pharmaceutically acceptable derivatives of the active ingredient include pharmaceutically acceptable metal ion salts, such as alkali metal salts, eg the di-sodium and di-potassium salts, and alkaline earth metal salts, eg the  
15 calcium and magnesium salts. We especially prefer the di-sodium salt, which is commonly known as nedocromil sodium.

The composition may contain from 0.5 to 20% w/w, preferably from 1.0 to 10% w/w, eg 4% w/w, of the active  
20 ingredient.

We prefer the composition to be a cream. The cream may be a water-in-oil cream or, more preferably, an oil-in-water cream.

The cream preferably includes one or more emulsifying agents. Suitable emulsifying agents for oil-in-water creams include sodium, potassium, ammonium and triethanolamine soaps; polysorbates; and cationic, anionic and non-ionic emulsifying waxes. For water-in-oil creams, suitable emulsifying agents include calcium soaps, wool fat, wool alcohols, beeswax and certain sorbitan esters.

The cream generally contains an effective proportion of a pharmaceutically acceptable preservative or sterilising agent suitable for a cream. Examples of preservatives which may be used are chlorbutol, chlorocresol, methyl p-hydroxybenzoate (either alone or in combination with propyl p-hydroxybenzoate) and thiomersal.

The preservative may be present at a level of from about 0.05 to 1.0% w/w, more preferably from about 0.1 to 0.5%, eg 0.2%.

The cream may be buffered at a pH of from 3.0 to 7.0, preferably at a pH of from 4.0 to 6.5, and more preferably at a pH of from 5.0 to 6.0.

Thus, according to a preferred aspect of the invention, there is provided an oil-in-water pharmaceutical cream buffered at a pH of from 3.0 to 7.0 and comprising, as active ingredient, sodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano (3,2-g)quinoline-2,8-dicarboxylate.

The oil phase of the oil-in-water cream preferably comprises liquid paraffin. The oil phase preferably includes one or more emulsifying agents, eg a long chain alcohol, such as cetostearyl alcohol, or a fatty acid ester, such as self-emulsifying glyceryl monostearate. The oil phase may also include one or more emollients, eg isopropyl myristate and one or more additional surfactants, eg one or more cetomacrogol ethers. The oil phase preferably constitutes from 20 to 40% w/w of the cream.

10 The water phase may include a buffering agent, eg the salt of a weak acid. Suitable acids include carboxylic acids, eg acetic acid and particularly citric acid. Suitable salts include alkali metal salts, eg sodium or potassium. The water phase may also include one or more  
15 bacteriocidal and/or fungicidal preservatives, eg potassium sorbate and methyl hydroxybenzoate.

In ointments, the active ingredient is preferably finely-divided and dispersed in a waxy, fatty, protein or paraffin base, preferably a soft paraffin base. Liquid  
20 paraffin, hard paraffin, and wool fat may be included in

. the ointment base.

We prefer to use ointments containing a major proportion (eg 70-90% w/w) of a white or yellow soft paraffin and optionally minor proportions of a liquid  
5 paraffin (5-15% w/w) and of a hard paraffin (0-12% w/w).

The ointment may also contain other liquid components, eg water or polyethylene glycol to improve the consistency of the base, provide a solvent for the active ingredient so that the active ingredient may be sterilised by filtration  
10 and/or to alter the rate of release of the active ingredient from the base.

Dusting powders may contain two or more ingredients intimately mixed in fine powder form. Alternatively, the active ingredient may be applied as a solution or  
15 suspension in a liquid carrier to the surface of a solid carrier and the coated particles dried. Examples of solid carriers, which are normally sterilised, are talc, starch,

20

25

lactose, zinc oxide, light kaolin and calcium carbonate.

Where solid particles of the active ingredient are present, eg in a suspension or dispersion or in a powder formulation, it is preferred that these have a mean  
5 particle size in the range 0.01 to 10 micrometres.

The compositions according to the invention may be prepared by mixing the ingredients, eg by dry mixing or by grinding the solid ingredients together, or by emulsifying an aqueous solution of the active ingredient with an  
10 appropriate oil base. The final pH of the solution may be controlled by the addition of an appropriate quantity of acid or base.

---

Creams may be made by dissolving the active ingredient in water buffered at the desired pH and adding  
15 the solution to the molten oil phase ingredients in a homogeniser at a temperature of from about 40 to 90°C. After homogenisation and cooling, the cream may be filled into suitable receptacles, eg tubes.

The composition is preferably administered to the  
20 skin of a patient merely by smearing or spreading the cream over the skin which is affected or likely to be affected.

The frequency of application of the composition will depend upon the severity of the disorder to be treated and  
25 the area of the skin over which it extends. Repeated



applications may be made at intervals during the day, eg from 1 to 6 times, preferably twice, a day. The composition may be applied prophylactically, but is more usually applied to an area which is already affected.

5       The composition finds use in the treatment of various disorders in mammals, notably man, cats, dogs and horses, including conditions which involve skin mast cells and/or delayed (cellular) hypersensitivity reactions and/or which involve inflammation.

10       The composition is of particular use in the treatment of atopic eczema in man.

Other specific conditions in man and other animals which may be treated include contact sensitivity, eg to chromium, nickel or an antibiotic; drug eruptions;

15   psoriasis; dermatitis; aphthous ulcers; Behcet's syndrome; pemphigus; urticaria; urticaria pigmentosa; the ulcers of Crohn's disease; pyoderma gangrenosum; chronic skin ulcers; burns; bee and wasp stings; herpetic infections; and dermatological disorders such as systemic sclerosis

20   (also known as systemic scleroderma), morphoea (also known as circumscribed or localised scleroderma) and dermal nodular fibrosis (also known as dermatofibroma) which involve excessive fibrosis.

Thus, according to a further aspect of the invention,

25   there is provided the use of 9-ethyl-6,9-dihydro-4,6-

dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable derivative thereof as active ingredient in the manufacture of a medicament for the treatment of a dermatological disorder which involves excessive fibrosis, by topical administration to the skin of a patient suffering from such a disorder.

The amount of the active agent to be administered will of course vary with the condition to be treated, the animal or patient to be treated, the particular derivative used and the mode of administration. However, generally satisfactory results can be achieved when the active agent is administered at a dosage of from about 1 to 100, and preferably 10 to 75mg per kg of animal body weight. For man the indicated daily dosage is in the range of from 1mg to 3500mg, preferably 1mg to 1500mg and more preferably from 1mg to 600mg, which may be administered in divided doses from 1 to 6 times a day. As is usual when treating a skin condition topically, eg using an cream, the dosage

20

25

is difficult to control, but will depend in general on the size and condition of the area to be treated.

The invention is illustrated, but in no way limited, by the following Examples.

5 Example 1 : Oil-in-Water Cream

Ingredients

	<u>Oil phase</u>	<u>% w/w</u>
	Glyceryl Monostearate BP	4.0
	Cetostearyl Alcohol BP	4.0
10	Liquid Paraffin BP	10.0
	Isopropyl Myristate BP	5.0
	Cremophor A6*	2.0
	Cremophor A25*	2.0
	Propyl Hydroxybenzoate BP	0.1
15	<u>Aqueous phase</u>	
	Methyl Hydroxybenzoate BP	0.1
	Potassium Sorbate BP	0.2
	Purified Water BP (low metal)	67.22
	Sodium Acid Citrate BP	1.3
20	Sodium Hydroxide BP	0.08
	Active ingredient:	4.0
	Sodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl -4H-pyrano(3,2-g)quinoline-2,8-dicarboxylate	

\* Cremophor A6 and Cremophor A25 are Trade Marks.

Method

The oil phase components are placed in a mixing bowl and melted with stirring at 60-70°C.

The active ingredient is added to the buffered  
5 aqueous phase, dissolved under gentle heating and then the  
warm aqueous layer added to the oil phase with vigorous  
stirring. When the addition and homogenisation is  
complete, the mixture is allowed to cool under gentle  
agitation and then filled into 20ml tubes at ambient  
10 temperature.

Example 2 : Oil-in-Water Cream

---

Ingredients

	<u>Oil phase</u>	<u>% w/w</u>
	Glyceryl Monostearate BP	4.0
15	Cetostearyl Alcohol BP	4.0
	Liquid Paraffin BP	15.0
	Cremophor A6*	2.0
	Cremophor A25*	2.0
	Propyl Hydroxybenzoate BP	0.1
20	<u>Aqueous phase</u>	
	Methyl Hydroxybenzoate BP	0.1
	Potassium Sorbate BP	0.2
	Purified Water BP (low metal)	67.22
	Sodium Acid Citrate BP	1.3
25	Sodium Hydroxide BP	0.08

Active ingredient: 4.0

Sodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl  
-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylate

\* Cremophor A6 and Cremophor A25 are Trade Marks.

5 Method

This composition was prepared by the method of Example 1 and showed improved preservation characteristics.

Example 3 : Ointment

	<u>Ingredients</u>	<u>% w/w</u>
10	Liquid Paraffin BP	10 <sup>8</sup>
	Wool Fat BP	10
	White Soft Paraffin BP	70
	Active Ingredient	10
	Sodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl	
15	-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylate	

Method

Prepared by dispersing finely divided active ingredient in a molten mixture of the other components in a mixing bowl at 60-70°C. After homogenisation, the mixture is allowed to cool and then filled into 20ml tubes at ambient temperature.

Example 4 : Dusting Powder

<u>Ingredients</u>	<u>% w/w</u>
Zinc oxide	25
Purified Talc	10
5 Sterilisable Maize Starch	55
Active Ingredient	10
Sodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl -4H-pyrano(3,2-g)quinoline-2,8-dicarboxylate	

Method

10 Prepared by grinding together the various ingredients.

Example 5 : Skin Permeation Measurements

Penetration of active ingredient through hairless mouse and human skin has been demonstrated in the following tests for various formulations:

15 Hairless mice, of either sex, aged 8-12 weeks were sacrificed by cervical dislocation, the dorsal skin excised and subcutaneous fat removed with minimal handling. Human epidermal membranes were prepared by immersing whole (epidermis plus dermis) skin in water at 60°C for 30  
20 seconds, removing and gently teasing off the

epidermis by means of blunt forceps. Care was taken to ensure minimal handling of the thin membrane. Samples were then mounted, epidermal side uppermost, onto a glass horizontal diffusion cell, a donor chamber fixed in position and clamped. The receiving medium was 50% aqueous ethanol (v/v) and the cells were mounted in a thermostatically controlled water bath at 37°C.

The formulation under test was applied evenly to the epidermal side of the sample. After a predetermined time, the receiving medium was removed, filtered and analysed for the active ingredient by high pressure liquid chromatography (HPLC).

15

20

25 0447L/saj

Claims

1. A pharmaceutical composition in the form of a cream, ointment or dusting powder, comprising, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable derivative thereof in admixture with a pharmaceutical acceptable adjuvant or excipient.
2. A composition according to Claim 1, wherein the active ingredient is in the form of a pharmaceutically acceptable metal ion salt.
3. A composition according to Claim 2, wherein the active ingredient is nedocromil sodium.
4. A composition according to any one of the preceding claims which contains from 0.5 to 20% w/w of active ingredient.
5. A composition according to Claim 4 which contains from 1.0 to 10% w/w of active ingredient.
6. A composition according to any one of the preceding claims which is a cream.
7. A composition according to Claim 6 which is an oil-in-water cream.
8. A composition according to Claim 6 or Claim 7 which has a pH of between 3.0 and 7.0.
9. A composition according to Claim 8, wherein the pH is between 4.0 and 6.5.



10. A composition according to Claim 9, wherein the pH is between 5.0 and 6.0.
11. An oil-in-water pharmaceutical cream buffered at a pH of from 3.0 to 7.0 and comprising, as active ingredient,  
5 sodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano  
(3,2-g)quinoline-2,8-dicarboxylate.
12. A composition according to any one of Claims 1 to 5 in the form of an ointment.
13. A composition according to any one of Claims 1 to 5 in  
10 the form of a dusting powder.
14. The use of 9-ethyl-6,9-dihydro-4,6-dioxo-10-  
propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a  
pharmaceutically acceptable derivative thereof as active  
ingredient in the manufacture of a medicament for the  
15 treatment of a dermatological disorder which involves  
excessive fibrosis, by topical administration to the skin  
of a patient suffering from such a disorder.
15. A use according to Claim 14, wherein the disorder to  
be treated is selected from the group consisting of  
20 systemic scleroderma, morphea and dermal nodular fibrosis.
16. A pharmaceutical composition according to Claim 1 and  
substantially as hereinbefore described.
17. A pharmaceutical cream according to Claim 6 and

substantially as hereinbefore described in Example 1 or Example 2.

18. The use according to Claim 14 of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable derivative thereof substantially as hereinbefore described.

---

10

15

20

25